72066023RFA00002: USAID Combating HIV/AIDS Through Local Partnership Activity (CHALPA)-Kinshasa
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Democratic Republic of the Congo USAID-Kinshasa notices from 2023.
Democratic Republic of the Congo USAID-Kinshasa offered grants of up to $14.9 million to the applicants described in the notice. It expected to make one award worth $14.9 million in total. Applications closed on July 11, 2023.
From the official notice on Grants.gov, last changed May 26, 2023. Checked November 7, 2026.
- Award ceiling$14.9 million
- Total funding$14.9 million
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 19, 2023 |
|---|---|
| Deadline | July 11, 2023 |
| Archived by Grants.gov | August 10, 2023 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility for this award is restricted to local entities as defined in ADS 303.6.
Is this a realistic fit?
- Past USAID Foreign Assistance for Programs Overseas awards averaged $8.7 million; this notice allows up to $14.9 million per award.
- Most of the program's money (54% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
The United States Agency for International Development in Democratic Republic of Congo (USAID/DRC) is seeking applications for a Fixed Amount Award (FAA) Cooperative Agreement from qualified entities to implement the USAID Combating HIV/AIDS Through Local Partnership Activity (CHALPA) Activity in Kinshasa. Eligibility for this award is restricted to local entities as defined in ADS 303.6. USAID DRC intends to fund the implementation of three (3) distinctive activities named Combating the HIV/AIDS epidemic Through Local Partnership Activity (CHALPA) in the following provinces: Kinshasa, Lualaba, and Haut-Katanga. These activities will work with the Government of the DRC (GDRC) and other USAID implementing partners to deliver high quality, accessible HIV/AIDS related services in selected provinces towards achieving HIV epidemic control. These activities will join the portfolio of partners implementing the President’s Emergency Plan for AIDS Relief (PEPFAR) program in the DRC. USAID/DRC envisions that this CHALPA award will focus on service delivery separately in five (5) health zones for CHALPA in Kinshasa. Solicitations for covering the remaining two provinces will be issued separately. The programs will collaborate with existing (EpiC/360, IHP/ABT, Chemonics Francophone Task Order) and new implementers across the project. The number of health zones supported in each province can change depending on PEPFAR and the GDRC orientations. The service delivery model intends that each activity in a specific province will include all aspects of HIV epidemic control, Orphans and Vulnerable Children (OVC) and some key populations (KPs) programming, to ensure smooth transition of the existing key populations program (EpiC). More details are available from full Notice of Funding Opportunity (NOFO) as posted with this synopsis. *The correct email address for submitting applications, sending questions, and POC contact would be "kinshasaproposals@usaid.gov" instead of "kishasaproposals@usaid.gov". The correction will be made in the NOFO through an amendment.
Who has won USAID Foreign Assistance for Programs Overseas grants before
From fiscal 2021 to 2025, USAID Foreign Assistance for Programs Overseas (98.001) awarded $37 billion across 4,233 grant awards, an average of $8.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Miscellaneous Foreign Awardees | District of Columbia | 489 | $6.9 billion |
| Family Health International | North Carolina | 91 | $2.1 billion |
| Catholic Relief Services - United States Conference of Catholic Bishops | Maryland | 128 | $1.2 billion |
| Save the Children Federation, Inc. | Connecticut | 100 | $814 million |
| Research Triangle Institute | North Carolina | 33 | $756 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is 72066023RFA00002 still open?
No. It closed on July 11, 2023.
Who can apply for USAID Combating HIV/AIDS Through Local Partnership Activity (CHALPA)-Kinshasa?
Democratic Republic of the Congo USAID-Kinshasa accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for USAID Combating HIV/AIDS Through Local Partnership Activity (CHALPA)-Kinshasa?
Closed July 11, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $14.9 million each. About $14.9 million in total for one award.
Who has won USAID Foreign Assistance for Programs Overseas grants before?
The largest recipients over five fiscal years were Miscellaneous Foreign Awardees, Family Health International, Catholic Relief Services - United States Conference of Catholic Bishops. The program made 4,233 awards worth $37 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)